Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.05
Bid: 3.80
Ask: 4.30
Change: 0.15 (3.85%)
Spread: 0.50 (13.158%)
Open: 3.90
High: 4.05
Low: 3.72
Prev. Close: 3.90
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

Wed, 13th Dec 2023 09:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Impellam Group PLC, up 26% at 819.12 pence, 12-month range 580.00p-950.00p. Shares in the staffing firm rise, though back off from new 52-week high, after it says it has agreed to a GBP483.2 million takeover offer from Heather Global PLC, a bidding vehicle for HeadFirst Global BV. The HeadFirst offer values each Impellam share at 1,084.4 pence in total. This represents a 67% premium over the stock's 650.00p close in London on Tuesday. The offer is supported by Impellam's majority owner Michael Ashcroft, a UK businessman who was formerly deputy chair of the UK Conservative Party.

----------

Allergy Therapeutics PLC, up 9.5% at 2.13p, 12-month range 0.37p-5.64p. The biotechnology firm, focused on allergy vaccines, updates on G306 Phase III trial of Grass MATA MPL, its short-course subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. It notes "highly significant secondary efficacy endpoints with an acceptable safety and tolerability profile observed for Grass MATA MPL." Chief Executive Manuel Llobet says: "We are very pleased that the primary and secondary endpoints from this trial strongly align, and all data analysed demonstrate the beneficial effect of our Grass MATA MPL product. These data, alongside the results from our earlier G309 field study, provide a strong, significant and consistent data package for our discussions with relevant health authorities."

----------

AIM - LOSERS

----------

Future Metals NL, down 12% at 1.30p, 12-month range 1.13p-6.40p. The West Perth-based exploration company focused on the Panton platinum group metals project in Western Australia says its shares have been suspended on the Australian Securities Exchange in Sydney pending the release of an announcement in relation to a "potential capital raising". The company's shares continue to trade as normal on AIM in London.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
19 Sep 2014 15:09

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
19 Sep 2014 05:25

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
18 Sep 2014 15:23

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
18 Sep 2014 05:23

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
17 Sep 2014 15:01

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
17 Sep 2014 08:34

UK BROKER RATINGS: Berenberg Raises Johnson Matthey To Buy

Read more
17 Sep 2014 05:19

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
16 Sep 2014 15:11

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
16 Sep 2014 05:26

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Sep 2014 15:11

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
24 Jul 2014 11:37

Allergy Therapeutics Full Year Revenues To Beat Market Expectations

Read more
30 Apr 2014 10:18

Allergy Therapeutics Says Licence Renewed At Worthing Facility

LONDON (Alliance News) - Allergy Therapeutics PLC said that following the recent inspection of its facilities in Worthing by the Medicines and Healthcare Products Regulatory Agency, the firm Wednesday received its Certificate of GMP Compliance for the site. The specialty pharmaceutical firm

Read more
25 Apr 2014 08:44

DIRECTOR DEALINGS: Allergy Therapeutics Executives Acquire Shares

LONDON (Alliance News) - Allergy Therapeutics PLC said Friday that Chief Executive Manuel Llobet and Finance Director Ian Postlewaite acquired shares at nil cost under the company's long term share incentive plan on Thursday, as follows:

Read more
17 Apr 2014 10:44

Allergy Therapeutics Extends Term Of Convertible Loan

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it had extended the term of its GBP4.04 million convertible loan with CFR International SpA. The maturity of the loan has been extended to September 30 from April 20, all other terms of the loan are unchanged. Shares

Read more
1 Apr 2014 09:39

Tuesday broker round-up UPDATE

African Barrick Gold: Deutsche Bank raises target price from 240p to 310p and keeps a hold recommendation. African Minerals: Deutsche Bank lowers target price from 399p to 382p, while its buy recommendation is kept. Allergy Therapeutics: Panmure Gordon ups target price from 16p to 25p and retains

Read more

Quickpicks are a member only feature

Login to your account